NeoCore Technology Co

NeoCore Technology Co AAQS

The The AAQS of NeoCore Technology Co (4131.TWO) as of Nov 11, 2026 is 5. In the previous year, The AAQS was 5.00 — a change of 0.00% (lower).

AAQS

5

YoY

0.00%

Last updated:

NeoCore Technology Co has a current AAQS of 5.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock NeoCore Technology Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The NeoCore Technology Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2017
5.00 TWD
Jan 1, 2018
5.00 TWD
Jan 1, 2019
5.00 TWD
Jan 1, 2020
5.00 TWD
Jan 1, 2021
5.00 TWD
Jan 1, 2022
5.00 TWD
Jan 1, 2023
5.00 TWD
Jan 1, 2024
5.00 TWD
The NeoCore Technology Co AAQS history
YEARAAQSYoY
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
50.00%
5—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoCore Technology Co Stock analysis

What does NeoCore Technology Co do? NeoCore Technology Co Ltd generates revenue through the sale of biochips and related biotechnology products. The company develops and manufactures DNA/RNA sample preparation kits, polymerase chain reaction kits, rapid hybridization equipment, biochips, testing reagents, biological preparations, nucleic acid sequencing detection systems, biotechnology control hardware and software, and biomedical materials. These products are primarily sold within Taiwan and exported to Asian and European markets. The company's domestic sales focus on the Taiwanese market while international exports target Asian and European customers. DR. Chip Biotechnology, Inc. operates as the parent company for NeoCore Technology Co Ltd, managing the research, development, manufacturing, and sales of biochips. The business model relies on direct sales of its comprehensive product portfolio to domestic and international clients in the biotechnology sector. The company's product range serves both laboratory and commercial applications within the biotechnology industry. NeoCore Technology Co Ltd's revenue streams include the sale of biochips, DNA/RNA sample preparation kits, polymerase chain reaction kits, and related components. The company's export focus on Asia and Europe drives international sales, while domestic sales in Taiwan form a significant portion of its business. The company's product offerings cater to the needs of biotechnology laboratories and commercial entities requiring advanced biotech solutions. NeoCore Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoCore Technology Co stock

The AAQS of NeoCore Technology Co is 5 in 2024.

On Eulerpool you can find the complete historical development of The AAQS NeoCore Technology Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — NeoCore Technology Co

All Key Metrics — NeoCore Technology Co